Economic Times. Why? The article states that CROs are packing up and moving other places in Asia Pacific because the Parliamentary Standing Committee recently rose questions as to the ethics used by the organizations and the treatment of those participating. In addition the organizations approving the drugs has switched over the past few years from the Drugs Controller General of India (DGCI) to New Drug Advisory Committee (NDAC). Many CROs believe Cambodia, Vietnam, Bangkok and Thailand are also more conducive to operating the clinical trials and doctors participate at lower costs than India.
This October in Shanghai, Julia Wu, Director, Global Pharmaceutical Sourcing, Asia Pacific, Janssen Research & Development and Ralf Altmeyer, Director General, Institut Pasteur Shanghai will be on hand to debate the current state of outsourcing in India and China, examining whether or not tough regulations and political confusion mentioned in this article are driving CROs to other countries to conduct clinical trials at Partnerships in Clinical Trials Asia. For more information on this session and the rest of the event, download the brochure here. If you're interested in joining us this September 12-14, 2012 in Shanghai, register today and mention code XP1775BLOG to save 15% off the standard rate!
With the complicated state of drug approval and regulation in India, do you see more CROs moving to conduct trials outside India?
The Partnerships in Clinical Trials Blog focuses on optimization intelligence, regulatory trends and globalization strategies for both sponsors and CROs. It is supported by a number of industry events.
Would you like to guest blog on our site? Or send us feedback? Send an email to firstname.lastname@example.org.